<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821726</url>
  </required_header>
  <id_info>
    <org_study_id>LNYY2020001</org_study_id>
    <nct_id>NCT04821726</nct_id>
  </id_info>
  <brief_title>DEB for Symptomatic Intracranial Atherosclerosis Stenosis</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of Drug Eluting Balloon Catheter for the Treatment of Patients With Symptomatic Intracranial Atherosclerosis Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yinyi(Liaoning) Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yinyi(Liaoning) Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, single-arm study to evaluate the safety and efficacy of drug&#xD;
      eluting balloon catheter for the treatment of patients with symptomatic intracranial&#xD;
      atherosclerotic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of&#xD;
      drug eluting balloon catheter (Vmoky) produced by Yinyi (Liaoning) Biotech Co., Ltd. for the&#xD;
      treatment of patients with symptomatic intracranial atherosclerotic stenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restenosis</measure>
    <time_frame>6 months (+60 days)</time_frame>
    <description>Restenosis was defined as greater than 50% stenosis within or immediately adjacent (within 5 mm) to the implanted balloon(s) or stent(s) and greater than 20% absolute luminal loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic success rate</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>TICI 3 blood flow, residual stenosis no more than 50% after 5 minutes and no flow-limited dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of device</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>device successfully cross the lesion and inflate, post-procedural residual stenosis no more than 50%, no use of bail-out stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of procedure</measure>
    <time_frame>In-hospital (Maximum 7 days after procedure)</time_frame>
    <description>Base on the device success, there is no stroke or death in-hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion stenosis</measure>
    <time_frame>6 months (+60 days) and 12 months (±60 days)</time_frame>
    <description>Calculate the stenosis degree with Quantitative Coronary Angiography (QCA) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis</measure>
    <time_frame>12 months (±60 days)</time_frame>
    <description>Restenosis was defined as greater than 50% stenosis within or immediately adjacent (within 5 mm) to the implanted balloon(s) or stent(s) and greater than 20% absolute luminal loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke events</measure>
    <time_frame>30 days (±7 days), 6 months (±60 days) and 12 months (±60 days)</time_frame>
    <description>Number of participants that occur these events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke and transient ischemic attack (TIA) in the area of the responsible blood vessels</measure>
    <time_frame>30 days (±7 days), 6 months (±60 days) and 12 months (±60 days)</time_frame>
    <description>Number of participants that occur these events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke and transient ischemic attack (TIA) out of the area of the responsible blood vessels</measure>
    <time_frame>30 days (±7 days), 6 months (±60 days), 12 months (±60 days)</time_frame>
    <description>Number of participants that occur these events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-stroke bleeding</measure>
    <time_frame>12 months (±60 days)</time_frame>
    <description>Number of participants that occur this event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days (±7 days), 6 months (±60 days) and 12 months (±60 days)</time_frame>
    <description>Number of participants that occur this event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events and adverse events</measure>
    <time_frame>12 months (±60 days)</time_frame>
    <description>Number of participants that occur these events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Cerebral Ischemia</condition>
  <condition>Cerebral Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Drug eluting balloon (Vmoky)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting balloon (Vmoky)</intervention_name>
    <description>Use Vmoky Drug Eluting Balloon to treat patients with symptomatic intracranial atherosclerosis stenosis</description>
    <arm_group_label>Drug eluting balloon (Vmoky)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 80 years old；&#xD;
&#xD;
          2. Symptomatic intracranial artery stenosis, the degree of intracranial diseased artery&#xD;
             vascular stenosis measured under cerebral angiography between 70~99% (WASID method)；&#xD;
&#xD;
          3. Symptoms are still recurrent after conservative medication (symptoms refer to stroke&#xD;
             and transient ischemic episodes of the brain)，or intracranial artery stenosis combined&#xD;
             with remote low perfusion performance (rCBF or rCBV abnormalities) in patients.&#xD;
&#xD;
          4. The stenotic vessels are located in the internal carotid artery (intracranial&#xD;
             segment), middle cerebral artery, vertebral artery (intracranial segment), basilar&#xD;
             artery, distal blood vessels are normal；&#xD;
&#xD;
          5. Only one lesion needed to be treated；&#xD;
&#xD;
          6. The intracranial artery needed to be treated l art mm in diameter；&#xD;
&#xD;
          7. Pre-expansion must be satisfied: forward blood flow TICI 3 level, pre-expanded guide&#xD;
             wire retention, observation for 5 minutes, residual stenosis is still ≤50%; without&#xD;
             blood limited dissection；&#xD;
&#xD;
          8. Patients have at least 1 porridge plaque risk factor, including past or existing&#xD;
             hypertension, diabetes, hyperlipidemia, smoking;&#xD;
&#xD;
          9. mRS≤3 points；&#xD;
&#xD;
         10. Patients or their guardians are able to understand the purpose of the trial,&#xD;
             voluntarily participate in and sign a written informed consent form, and receive&#xD;
             follow-up visits from patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target lesion is in-stent restenosis；&#xD;
&#xD;
          2. Exist lesion stenosis more than 50% out of the target vessel；&#xD;
&#xD;
          3. Intracranial haemorrhage occurred within 3 months (substantial cerebral hemorrhage,&#xD;
             large amount of subcranial hemorrhage, subdural/external bleeding)；&#xD;
&#xD;
          4. Acute ischemic stroke has occurred in the last two weeks；&#xD;
&#xD;
          5. Stenosis caused by non-atherosclerosis: e.g. arterial mezzanine, moya-moya disease,&#xD;
             vasculitis, radioactive vascular disease or fibrous muscle dysplasia;&#xD;
&#xD;
          6. Severe calcified, angulate and Mori type C lesions, as well as congenital development&#xD;
             of thin blood vessels and fenestration；&#xD;
&#xD;
          7. Combine intracranial tumors, aneurysms, or intracranial venous malformations；&#xD;
&#xD;
          8. There are risk factors that can lead to cardiogenic embolism: fibrillation,&#xD;
             left-ventricle thrombosis, mycardial infarction within 6 weeks, etc；&#xD;
&#xD;
          9. Uncontrollable hypertension by medication (Systolic pressure≥ystolic pres diastolic&#xD;
             blood pressure≥pressurec；&#xD;
&#xD;
         10. Severe combined or unstable conditions, such as severe heart failure, lung failure or&#xD;
             kidney failure (serum creatinine&gt;3.0mg/dL (264 μmol/L) or renal cyspheric filtration&#xD;
             rate (GFR) &lt;30ml/min), severe liver insequencies, malignant tumors;&#xD;
&#xD;
         11. A history of gastrointestinal haemorrhage or haemorrhagic disease (e.g. idiopathic&#xD;
             platelet reduction cyanosis, etc.) or a history of bleeding tendencies within 6 months&#xD;
             prior to the signing of the informed consent；&#xD;
&#xD;
         12. Hemoglobin is below 90g/L, plateplates&lt;90×109/L；&#xD;
&#xD;
         13. The International Standardized Rate (INR) &gt;1.5, with unreal corrective bleeding&#xD;
             factors；&#xD;
&#xD;
         14. Can not carry out antiplatelet/anticoagulant treatment, with anaesthetic and contrast&#xD;
             agent contraindication;&#xD;
&#xD;
         15. The angiography shows that the vascular path is curly, and the device is difficult to&#xD;
             reach the target position or to withdraw；&#xD;
&#xD;
         16. Patients known to be allergic to heparin, paclitaxel, contrast, aspirin and&#xD;
             clopidogrel, anesthetics;&#xD;
&#xD;
         17. Life expectancy is less than 1 year；&#xD;
&#xD;
         18. Participants in other drug or device clinical trials that have not been completed；&#xD;
&#xD;
         19. A pregnant or lactating woman, or a person planning to become pregnant within one&#xD;
             year；&#xD;
&#xD;
         20. Other conditions that the researchers consider patients are not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tianxiao Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyue Hua</last_name>
    <phone>+8618624429311</phone>
    <email>huaxy@dlyinyi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kai Yan</last_name>
    <phone>+8613940849959</phone>
    <email>yank@dlyinyi.com</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

